Our Pipeline
Our Pipeline
Our programs are first-in-class and internally generated, each representing an opportunity to make a transformational impact across numerous diseases with high unmet need.
Harnessing SIRP Biology to Target Pathogenic Immune Cells
We are advancing a novel portfolio of SIRP-directed therapies designed to selectively target the activated immune cells that drive disease. Our programs are built on a deep understanding of SIRP biology and have the potential to address a broad range of immune-mediated diseases and cancer with significant unmet need.
SIRP: signal regulatory protein; NK: natural killer
*Ipsoprubart and ELA822 are investigational products currently under evaluation. FDA and other regulatory authorities have not approved ipsoprubart or ELA822 as safe or effective for any indication.
Learn how ipsoprubart (ELA026) is designed to address the underlying drivers of sHLH
Learn how ELA822 is designed to selectively deplete activated, disease-driving T cells in immune-mediated diseases
SIRP: signal regulatory protein; NK: natural killer
*Ipsoprubart and ELA822 are investigational products currently under evaluation. FDA and other regulatory authorities have not approved ipsoprubart or ELA822 as safe or effective for any indication.
Learn how ipsoprubart (ELA026) is designed to address the underlying drivers of sHLH
Learn how ELA822 is designed to selectively deplete activated, disease-driving T cells in immune-mediated diseases